Inactive Instrument

CBD Global Sciences

CBDN

CA12482U1057

CBD Global Sciences Inc. announced that it has received $0.085 million in funding

March 23, 2022

On March 24, 2022, CBD Global Sciences Inc. closed the transaction. The transaction included participation from arm's length investors.

Latest news about CBD Global Sciences

CBD Global Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-12-02	CI
CBD Global Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-10-13	CI
CBD Global Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-10-06	CI
CBD Global Sciences Inc. Auditor Raises 'Going Concern' Doubt	22-10-05	CI
CBD Global Sciences Inc. cancelled the acquisition of Pure BioPlastics Inc.	22-05-31	CI
CBD Global Sciences Inc. Announces Change of Chief Financial Officer	22-04-26	CI
CBD Global Sciences Inc. Appoints Ed Lehrburger to the Board of Directors	22-03-24	CI
CBD Global Sciences Inc. announced that it has received $0.085 million in funding	22-03-23	CI
CBD Global Sciences Inc. executed a binding letter of intent to acquire Pure BioPlastics Inc.	22-03-23	CI
CBD Global Sciences Inc. announced that it expects to receive $0.085 million in funding	22-03-20	CI
CBD Global Sciences, Inc. Announces the Successful Launch of Rap Snacks in the Colorado Market That Exceeded First Week Sales Expectations	22-02-16	CI
CBD Global Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-29	CI
CBD Global Sciences, Inc. Approves the Appointment of Jeff Hays to the Board of Directors	21-10-19	CI
CBD Global Sciences Inc. completed the acquisition of Resinosa LLC.	21-10-14	CI
CBD Global Sciences Inc. executed a definitive agreement to acquire Resinosa LLC.	21-09-29	CI
Cbd Global Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-09-16	CI
CBD Global Sciences Inc. Auditor Raises 'Going Concern' Doubt	21-09-15	CI
CBD Global Sciences Inc. for Alzheimer's Treatment Reduces Plaque Buildups in the Brain That Causes Disease	21-04-05	CI
Medical College of Georgia in Augusta University Reveals CBD Global Sciences Inc. Treatment Reduces Plaque Buildups in the Brain That Causes Alzheimer’s Disease	21-03-25	CI
Legacy Distribution Group, a Subsidiary of CBD Global Sciences, to Begin Distribution for LIFEAID Beverage Co.(R)	21-03-17	CI
CBD Global Sciences Inc. Launches Legacy Distribution Group, a Distribution Company That Focuses on CBD Infused Products	21-02-18	CI
Ed McCaffrey and CBD Global Sciences Sign A Two-Year Endorsement Agreement with Aethics(TM)	21-01-13	CI
CBD Global Sciences, Inc. Announces to Launch of the New CBD Product Line Dog Unleashed CBD	21-01-07	CI
Dog the Bounty Hunter Signs A Two-Year Partnership with CBD Global Sciences to Create and Sell ‘Dog Unleashed CBD’	20-12-15	CI
Cbd Global Sciences Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-10-15	CI

CBD Global Sciences Inc. is a Canada-based cannabidiol (CBD) producer. The Company is engaged in the business of producing and selling industrial hemp derived CBD infused consumable and topical products, including CBD oil tincture drops, CBD hydration beverages, and CBD topicals. It markets and sells its own brand of CBD oil and byproducts under the Aethics and CannaOil brands (Products), which includes CBD Oil tinctures (liquid products), capsules, topicals, hydration products and confectionary products. Its hemp-derived CBD extracts are sold through distributors, brick and mortar retailers and online. The Company, through its subsidiaries, Global Sciences Holdings, Resinosa LLC and Legacy Distribution Group, is delivering CBD products both in retail and e-commerce formats. It also operates a manufacturing division, Resinosa LLC, with its capabilities to provide current good manufacturing practices (cGMP) to the CBD industry with both private label and white label CBD product lines.

Sector

More about the company